Abbott and Reata Pharmaceuticals recently announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl, which is currently in late Phase 2 trials for the treatment of chronic kidney disease.
Abbott and Reata Pharmaceuticals announce agreement to develop